Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Premenopausal Breast Cancer
Interventions: DRUG: Pembrolizumab/ Exemestane/ Leuprolide
Sponsor: National Taiwan University Hospital
Collaborators: Merck Sharp & Dohme LLC